scholarly journals The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury

2018 ◽  
Vol 9 ◽  
Author(s):  
Anandharajan Rathinasabapathy ◽  
Alana Horowitz ◽  
Kelsey Horton ◽  
Ashok Kumar ◽  
Santhi Gladson ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Angiotensin Ii ◽  
Lung Injury ◽  
Experimental Model ◽  
Lung Fibrosis ◽  
Receptor Agonist ◽  
Compound 21

scholarly journals Angiotensin II type 2 receptor agonist Compound 21 attenuates pulmonary inflammation in a model of acute lung injury

2018 ◽  
Vol Volume 11 ◽  
pp. 169-178 ◽  
Author(s):  
Mario Menk ◽  
Jan Adriaan Graw ◽  
Clarissa von Haefen ◽  
Henrik Kurt Alexander Steinkraus ◽  
Burkhard Lachmann ◽  
...  
Keyword(s):  
Acute Lung Injury ◽  
Angiotensin Ii ◽  
Lung Injury ◽  
Receptor Agonist ◽  
Pulmonary Inflammation ◽  
Compound 21

Protective effects of the angiotensin II AT2 receptor agonist compound 21 in ischemic stroke: a nose-to-brain delivery approach

2018 ◽  
Vol 132 (5) ◽  
pp. 581-593 ◽  
Author(s):  
Douglas M. Bennion ◽  
Chad H. Jones ◽  
Alex N. Dang ◽  
Jacob Isenberg ◽  
Justin T. Graham ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Angiotensin Ii ◽  
Receptor Agonist ◽  
At2 Receptor ◽  
Protective Effects ◽  
Neuroprotective Effects ◽  
Receptor Agonists ◽  
Compound 21 ◽  
Neuroprotective Actions

Significant neuroprotective effects of angiotensin II type 2 (AT2) receptor (AT2 receptor) agonists in ischemic stroke have been previously demonstrated in multiple studies. However, the routes of agonist application used in these pre-clinical studies, direct intracerebroventricular (ICV) and systemic administration, are unsuitable for translation into humans; in the latter case because AT2 receptor agonists are blood–brain barrier (BBB) impermeable. To circumvent this problem, in the current study we utilized the nose-to-brain (N2B) route of administration to bypass the BBB and deliver the selective AT2 receptor agonist Compound 21 (C21) to naïve rats or rats that had undergone endothelin 1 (ET-1)-induced ischemic stroke. The results obtained from the present study indicated that C21 applied N2B entered the cerebral cortex and striatum within 30 min in amounts that are therapeutically relevant (8.4–9 nM), regardless of whether BBB was intact or disintegrated. C21 was first applied N2B at 1.5 h after stroke indeed provided neuroprotection, as evidenced by a highly significant, 57% reduction in cerebral infarct size and significant improvements in Bederson and Garcia neurological scores. N2B-administered C21 did not affect blood pressure or heart rate. Thus, these data provide proof-of-principle for the idea that N2B application of an AT2 receptor agonist can exert neuroprotective actions when administered following ischemic stroke. Since N2B delivery of other agents has been shown to be effective in certain human central nervous system diseases, the N2B application of AT2 receptor agonists may become a viable mode of delivering these neuroprotective agents for human ischemic stroke patients.

Effect of Compound 21, a Selective Angiotensin II Type 2 Receptor Agonist, in a Murine Xenograft Model of Dupuytren Disease

2017 ◽  
Vol 140 (5) ◽  
pp. 686e-696e ◽  
Author(s):  
Jessica Chisholm ◽  
Alison J. Gareau ◽  
Stephanie Byun ◽  
Justin L. Paletz ◽  
David Tang ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Receptor Agonist ◽  
Xenograft Model ◽  
Murine Xenograft Model ◽  
Compound 21 ◽  
Dupuytren Disease

Angiotensin ii type 2 receptor agonist, compound 21, prevents tubular epithelial cell damage caused by renal ischemia

2021 ◽  
pp. 114804
Author(s):  
Fussi María Fernanda ◽  
Hidalgo Florencia ◽  
Buono Gabriel ◽  
Marquez Susana Beatriz ◽  
Pariani Alejandro ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Epithelial Cell ◽  
Receptor Agonist ◽  
Cell Damage ◽  
Tubular Epithelial Cell ◽  
Renal Ischemia ◽  
Compound 21

C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction

2015 ◽  
Author(s):  
Anandharajan Rathinasabapathy ◽  
Alana Horowitz ◽  
Kelsey Horton ◽  
Ulrike Steckelings ◽  
Thomas Unger ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Cardiac Dysfunction ◽  
Lung Fibrosis ◽  
Receptor Agonist

scholarly journals The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis

Diabetologia ◽  
2016 ◽  
Vol 59 (8) ◽  
pp. 1778-1790 ◽  
Author(s):  
Bryna S. M. Chow ◽  
Christine Koulis ◽  
Pooja Krishnaswamy ◽  
Ulrike M. Steckelings ◽  
Thomas Unger ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Receptor Agonist ◽  
Experimental Diabetes ◽  
Compound 21

scholarly journals The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome

2018 ◽  
Vol 71 (4) ◽  
pp. 215-222 ◽  
Author(s):  
Peter Verbrugghe ◽  
Jelle Verhoeven ◽  
Marnick Clijsters ◽  
Dominique Vervoort ◽  
Jarne Schepens ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Aortic Aneurysm ◽  
Mouse Model ◽  
Marfan Syndrome ◽  
Receptor Agonist ◽  
Aneurysm Growth ◽  
Compound 21
Sign in / Sign up

Export Citation Format

Share Document